<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>CLINICAL DYNAMICS OF HEMOSTATIC SYSTEM PARAMETERS AND THE ROLE OF BIOMARKERS IN PATIENTS WITH IMMUNE MICROTHROMBOVASCULITIS UNDER ANTICOAGULANT THERAPY</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Z.Ch.</mods:namePart><mods:namePart type="family">Kurbanova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Sayfuddinova</mods:namePart><mods:namePart type="family">Z.A</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">.A.</mods:namePart><mods:namePart type="family">Begmatova3</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Immune microthrombovasculitis (IMTV) is a rare disorder characterized by immune-mediated microvascular thrombosis, often requiring anticoagulant therapy to mitigate thrombotic complications. This prospective study investigates the dynamics of hemostatic system parameters (D-dimer, fibrinogen, prothrombin time [PT], activated partial thromboplastin time [APTT]) and biomarkers (von Willebrand factor [vWF], C-reactive protein [CRP]) in 40 patients with IMTV over a 12-month period. Patients received either warfarin or direct oral anticoagulants (DOACs). Significant reductions in D-dimer levels (from 1.3 µg/mL to 0.5 µg/mL, p&amp;lt;0.01) and stabilization of APTT were observed in 85% of DOAC-treated patients. Fibrinogen levels remained elevated in 55% of patients, correlating with CRP (r=0.68, p&amp;lt;0.01). Elevated vWF levels at baseline (185 IU/dL) decreased modestly (145 IU/dL, p=0.04), reflecting partial endothelial recovery. Persistent vWF elevation was associated with a 20% incidence of recurrent thrombotic events. These findings underscore the utility of hemostatic parameters and biomarkers in monitoring therapy efficacy and predicting outcomes, advocating for personalized treatment strategies in IMTV.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-06-09</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Center for Tech and Media Research</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>